Cancer-related lymphedema

Genevieve Chaput MD MA CCFP(PC) Marize Ibrahim MSc PT

ymphedema is an inflammatory condition caused by the accumulation of lymphatic fluid due to damage to the lymphatic system. There are 2 classifications of lymphedema: primary, which is caused by malformation of lymph vessels or nodes, and secondary, which is due to trauma, chronic lymphatic system overload, or cancer and its treatments. This article focuses on cancer-related lymphedema, which can develop within weeks, months, or years following oncologic treatments.1 Herein we present an overview of epidemiology, risk factors, history and physical examination for clinical diagnosis, as well as criterion-standard management for this condition in the primary care setting.

What are the main functions of the lymphatic system?

The lymphatic system is a network of tissues, vascular channels, and organs responsible for moving lymph back into the circulatory system.² Approximately 20 L of plasma flow throughout the body's arteries and blood vessels daily. An estimated 16 L to 17 L are reabsorbed into the circulatory system, with the remaining 3 L to 4 L seeping into tissues and being recovered by the lymphatic system. The lymphatic system's main functions are to maintain fluid levels in the body, absorb digestive tract fats, protect the body against invaders that could cause illness, and remove cellular waste products.3

Epidemiology, pathophysiology, and risk factors of cancer-related lymphedema

The absence of a universal definition and standardized diagnostic criteria renders cancer-related lymphedema prevalence difficult to determine, and it is likely underreported.4 Cancer location and types of treatment influence cancer-related lymphedema incidence, with estimates ranging from 5% to 83% with different malignancies.⁵⁻⁸ Due to its high prevalence, breast cancer is the most common cause of secondary lymphedema among patients in developed countries.9 Moreover, cancer-related lymphedema occurs in approximately 1 in 6 patients with a history of melanoma, sarcoma, or gynecologic or genitourinary cancer.10 Head and neck tumours are also commonly associated with lymphedema, which can contribute to debilitating dysphagia.11 Estimates suggest that cancer-related lymphedema affects more than 300,000 individuals in Canada.12

Cancer-related lymphedema can develop as a result of obstruction of lymphatic channels or nodes by tumour compression, tumour cell infiltration of the lymphatic vessels (ie, lymphangitic carcinomatosis), lymph node dissection or removal, lymphatic channel destruction

from radiotherapy, or chemotherapy agents such as taxanes.13 Other noncancer-related risk factors also increase the risk of developing lymphedema, including trauma, overweight or obese status, chronic venous insufficiency, deep vein thrombosis (DVT), and cellulitis (Box 1).14,15

How is lymphedema diagnosed?

Cancer-related lymphedema is a straightforward diagnosis based on history and physical examination findings.4,16,17 Given the considerable psychosocial and physical burdens associated with more advanced stages, early identification of cancer-related lymphedema is

Box 1. Lymphedema site risk factors

Upper limb or trunk lymphedema

- · Axillary lymph node dissection
- · Radiotherapy to the breast
- · Radiotherapy to lymph nodes (axillary, internal mammary or subclavicular lymph nodes)
- Chemotherapy (taxanes)
- · Skin changes following axillary radiotherapy (fibrosis, radiodermatitis)
- · Complications from wounds or drains
- · Axillary web syndrome
- · Lymphocele
- Advanced cancer
- · Overweight or obese status
- · Cellulitis and inflammatory skin conditions
- · High blood pressure
- · Procedures such as pacemaker insertion and arteriovenous shunt for dialysis
- Filariasis

Lower limb lymphedema

- Lymphatic vessel compression due to tumour location (pelvic or abdominal tumours)
- · Inguinal or pelvic lymph node dissection
- Pelvic radiotherapy
- Deep vein thrombosis and post-thrombotic syndrome
- Comorbid conditions (cardiac or renal disease)
- Advanced cancer
- · Overweight or obese status
- Chronic venous insufficiency
- · Varicose vein treatments (stripping)
- · Cellulitis and inflammatory skin conditions
- Orthopedic surgery
- · Prolonged limb immobilization
- · Genetic predisposition
- Filariasis

Head and neck

- · Surgical neck dissection
- Radiotherapy

Reproduced under the Creative Commons Attribution 2.0 Generic License.14,15 Copyright 2020 Multimed Inc.

paramount to minimize disease progression. 1,16-18 For patients undergoing cancer treatment or with a history of cancer, family physicians can aptly screen for lymphedema risk factors and inquire about potential early signs and symptoms of this condition.

Focused history elements

In addition to a general medical assessment including previous medical, surgical, and social history, assessment of cancer-related lymphedema and other conditions associated with swelling should be performed (Box 2), with particular attention to congestive heart failure, renal failure, liver or venous insufficiency, and DVT.17

Onset is usually insidious in nature. Early signs and symptoms of upper or lower limb cancer-related lymphedema include patient reports of clothes or jewellery feeling tighter on the affected limb (eg, tightness of finger rings, wristwatches, clothing sleeves, or footwear). Sensation of fullness or heaviness complaints of the affected limb and adjacent areas (chest, trunk, pelvic, genital) are also common, while intermittent limb swelling of the cancer-treated area is pathognomonic of lymphedema.1,19 Head and neck cancer-related lymphedema can present as partial or extensive swelling of the oral cavity and-or neck areas. Swelling is often reported as worse upon awakening, with gradual improvement throughout the day with standing and activity. Head and neck lymphedema can also occur internally in the absence of external swelling. In these cases, swallowing difficulties, voice changes, and sensation of a foreign body lodged in the throat are commonly reported.11 While pain may be reported, severe pain is not typically suggestive of cancer-related lymphedema and thus should lead family physicians to rule out other potential underlying causes, including cancer recurrence.

Targeted physical examination

Along with body weight and body mass index measurements, evaluation of the vascular system and palpation of the lymph nodes proximal to the affected limb or area should be performed. Assessment of both affected and nonaffected limbs or areas should systematically include a series of examinations.

Box 2. Swelling complaint evaluation

- · Cardinal signs: location, quality, radiation, intensity, severity, alleviating or aggravating factors, and associated symptoms
- · Pattern of swelling: insidious versus acute onset, following a trigger event (eg, cellulitis, trauma)
- Nature of swelling: intermittent versus omnipresent
- · Identification of nononcologic and oncologic risk factors for lymphedema
- · Review of prescribed and over-the-counter medications that may contribute to edema

Dermatologic examination. This is an assessment of skin integrity, including the presence of dryness, erythema, pachydermia, and hyperkeratotic appearance (verrucous and vesicular lesions). Evidence of lymphorrhea and underlying fungal infection or open wounds secondary to chronic diseases such as diabetes should also be noted.

Pitting test. Application of firm pressure to the edematous tissue is done for at least 30 seconds. Skin indentation after release indicates pitting edema, which can be mild or more pronounced in any lymphedema stages. In advanced stages, however, pitting is usually less pronounced due to pachydermia and fibrosis.

Stemmer sign. Pinching of skin at the base of the second toe or finger assesses for thickened skin fold. Difficulty in lifting the skin indicates a positive Stemmer sign, which can be present at any lymphedema stage.

Vascular examination. This test documents presence of varicose veins and signs of chronic venous insufficiency. For lower limbs, evaluation of pedal pulses is advised if peripheral arterial disease is suspected, as compression therapy is contraindicated in this disease.

Limb volume difference should also be determined by measuring the circumference of both affected and unaffected limbs at different anatomical landmarks. Head and neck landmarks are also used to perform measurements. Serial measurements, which are typically performed by a trained therapist, aid in assessing lymphedema evolution and treatment response but are not mandatory in diagnosing lymphedema.

Although imaging is not routinely used for lymphedema diagnosis, some investigations may be warranted if another condition is suspected, such as a duplex ultrasound to rule out DVT. If peripheral arterial disease is suspected, ankle brachial index test is relevant, especially if compression therapy is considered. Based on history and examination findings, lymphedema diagnosis is classified into 4 stages (Box 3; Figures 1 and 2). 20-23

Management

Cancer-related lymphedema is an incurable disease requiring sustained patient support and adherence to a chronic disease management model.²⁴ The criterion standard of lymphedema management is decongestive lymphatic therapy,²⁵⁻²⁷ which aims to educate patients about the condition; decrease affected limb volume and fibrosis; optimize functional status; address body image concerns and improve quality of life; and promote patient engagement and self-management.

Decongestive lymphatic therapy comprises 2 phases: volume reduction and maintenance. 16,28 When indicated, the reduction phase aims to decrease the size of the affected limb to the smallest size attainable. To reduce volume, multilayer short-stretch inelastic bandages are worn

for 24 to 72 hours at a time (and then reapplied), and to increase venous and lymphatic flow, optimal skin care and regular exercises are performed. Alternatively, in patients with comorbid conditions or functional limitations. Velcro devices can be used.14 Reduction is carried out for 2 to 6 weeks depending on reduction requirements.

The maintenance phase aims to maintain limb volume size and requires patient engagement. Best outcomes for this lifelong phase are achieved through adherence to compression therapy, healthy lifestyle habits, and risk reduction strategies.

Box 3. International Society of Lymphology lymphedema staging definitions

Stage 0

· A subclinical state where swelling is not evident despite impaired lymph transport. This stage may exist for months or years before edema becomes evident

Stage I

· This represents early onset of the condition where there is accumulation of tissue fluid that subsides with limb elevation. The edema may be pitting at this stage

· Limb elevation alone rarely reduces swelling and pitting is manifest

Late stage II

 There may or may not be pitting as tissue fibrosis is more evident

Stage III

• The tissue is hard (fibrotic) and pitting is absent. Skin changes such as thickening, hyperpigmentation, increased skin folds, fat deposits, and warty overgrowths develop

Compression therapy. Medically prescribed compression garments (eg, sleeve, glove, knee- or thigh-high stocking) are preferably worn daily for as many hours as possible during the day. These garments are prescribed in classes ranging from 15 mm Hg to 50 mm Hg depending on the affected limb and severity. Nighttime garments may also be indicated, such as those for head and neck lymphedema. Compression garments are available in standard and custom-made sizes. Prescription should also include donning and doffing instruments to encourage optimal adherence. 16,28 A tool to facilitate prescribing is available in Figure 3, with a printable version available from CFPlus.* Contraindications to compression therapy should be reviewed (Box 4).14,15


Healthy lifestyle habits. Weight management and routine physical activity are essential to promote lymphatic and venous flow.

Risk reduction strategies. As lymphedema increases the risk of cellulitis, adherence to pristine skin care is essential to minimize infection risk and wound development. 9,29

In addition to providing support and education, family physicians can prescribe compression therapy, refer patients to certified lymphedema therapists for co-management, and ensure follow-up visits occur every 6 to 12 months, as indicated. Lymphedema associations across Canada provide educational resources for patients, registries of local fitters and therapists, and information on provincial plans for compression garment reimbursement (Box 5).

*A printable version of **Figure 3** is available from https://www.cfp.ca. Go to the full text of the article online and click on the CFPlus tab.

Figure 1. Examples of upper limb lymphedema stages



Reproduced under the Creative Commons Attribution-ShareAlike 4.0 International License.20

Figure 2. Examples of lower limb lymphedema stages



Reproduced under the Creative Commons Attribution-ShareAlike 4.0 International License.21

Figure 3. Tool to facilitate compression therapy prescription

⊒ Multi-layer bandage	kit for reduction therapy
☐ Compression garmen	t(s) for daytime use:
☐ Sleeve, class:	☐ 15-20 mm Hg or 15-21 mm Hg ☐ 20-30 mm Hg or 23-32 mm Hg ☐ 30-40 mm Hg or 34-46 mm Hg
☐ Glove, class:	☐ 15-20 mm Hg or 15-21 mm Hg ☐ 20-30 mm Hg or 23-32 mm Hg
☐ Velcro device	
☐ Compression garmen	t for nighttime use
☐ Breast swell spot (if b	oreast involvement)
☐ Donning and doffing	instruments
Renew x 12	
Diagnosis: Right, left, o	r bilateral lower limb lymphedema
☐ Multi-layer bandage	kit for reduction therapy for right, left,
☐ Multi-layer bandage or bilateral limb(s)	kit for reduction therapy for right, left,
□ Multi-layer bandage or bilateral limb(s) □ Compression garmen	kit for reduction therapy for right, left, t(s) for daytime use: 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg 30-40 mm Hg or 34-46 mm Hg
☐ Multi-layer bandage or bilateral limb(s) ☐ Compression garmen ☐ Knee high, class:	kit for reduction therapy for right, left, t(s) for daytime use: 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg 30-40 mm Hg or 34-46 mm Hg 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg
□ Multi-layer bandage or bilateral limb(s) □ Compression garmen □ Knee high, class: □ Thigh high, class:	kit for reduction therapy for right, left, t(s) for daytime use: 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg 30-40 mm Hg or 34-46 mm Hg 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg
□ Multi-layer bandage or bilateral limb(s) □ Compression garmen □ Knee high, class: □ Thigh high, class:	kit for reduction therapy for right, left, t(s) for daytime use: 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg 30-40 mm Hg or 34-46 mm Hg 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg t for nighttime use genital involvement)
□ Multi-layer bandage or bilateral limb(s) □ Compression garmen □ Knee high, class: □ Thigh high, class: □ Compression garmen □ Genital swell spot (if	kit for reduction therapy for right, left, t(s) for daytime use: 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg 30-40 mm Hg or 34-46 mm Hg 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg t for nighttime use genital involvement)
□ Multi-layer bandage or bilateral limb(s) □ Compression garmen □ Knee high, class: □ Thigh high, class: □ Compression garmen □ Genital swell spot (if □ Donning and doffing Renew x 12	kit for reduction therapy for right, left, t(s) for daytime use: 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg 30-40 mm Hg or 34-46 mm Hg 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg tfor nighttime use genital involvement) instruments
□ Multi-layer bandage or bilateral limb(s) □ Compression garmen □ Knee high, class: □ Thigh high, class: □ Compression garmen □ Genital swell spot (if □ Donning and doffing Renew x 12 Diagnosis: head and ne	kit for reduction therapy for right, left, t(s) for daytime use: 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg 30-40 mm Hg or 34-46 mm Hg 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg t for nighttime use genital involvement) instruments
□ Multi-layer bandage or bilateral limb(s) □ Compression garmen □ Knee high, class: □ Thigh high, class: □ Compression garmen □ Genital swell spot (if □ Donning and doffing Renew x 12	kit for reduction therapy for right, left t(s) for daytime use: 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg 30-40 mm Hg or 34-46 mm Hg 15-20 mm Hg or 18-21 mm Hg 20-30 mm Hg or 23-32 mm Hg t for nighttime use genital involvement) instruments

Box 4. Contraindications and precautions of compression

Contraindications

- Arterial insufficiency
- · Severe peripheral arterial occlusive disease
- · Acute cellulitis
- · Uncontrolled cardiac failure
- · Acute dermatitis
- · Severe diabetic neuropathy with sensory loss or microangiopathy with risk of skin necrosis
- · True allergy to compression material

Precautions

- · Signs of possible infection (cellulitis)
- Neuropathy
- · Nonambulatory patients

Reproduced under the Creative Commons Attribution 2.0 Generic License. 14,15 Copyright 2020 Multimed Inc.

Box 5. Lymphedema associations in Canada and patient resources

Lymphedema associations

- Newfoundland and Labrador: https://lymphnl.com
- Nova Scotia: https://lymphedemanovascotia.com
- · Quebec: http://en.infolympho.ca
- · Ontario: https://www.lymphontario.ca
- · Manitoba: https://www.lymphmanitoba.ca
- Saskatchewan: https://www.sasklymph.ca
- · Alberta: http://www.albertalymphedema.com
- British Columbia: https://bclymph.org

Additional resources for patients

 Canadian Lymphedema Framework: https://www.canadalymph.ca/patienteducationmaterials/

Clinical pearls

Rapid, rather than insidious, onset of limb swelling associated with skin changes should trigger family physicians to rule out malignancy. Diuretics are not recommended¹⁷; diuretics reduce swelling via excess water removal, but proteins remain in soft tissues, thereby drawing water back, which can exacerbate lymphedema and increase fibrosis and inflammation.³⁰ While surgical interventions such as lymph node transfers and lymphaticovenous anastomosis are being studied, decongestive lymphatic therapy remains the cornerstone of management.

Conclusion

Family physicians are well-suited to provide care for most patients with cancer-related lymphedema and can have a meaningful impact on their lives by doing so. For patients with more complex or advanced cases, referral to a physician with expertise in lymphedema may be considered.

Dr Genevieve Chaput holds a Casley-Smith certification in lymphedema; is Assistant Professor at McGill University in Montréal, Que; is an attending physician at the McGill University Health Centre (MUHC); and is Medical Chief of supportive and palliative care services at the Lachine Hospital of the MUHC. Marize Ibrahim is a lymphedema therapist and physical therapist specializing in oncology at the lymphedema clinic of the MUHC.

Competing interests

None declared

- 1. Denlinger CS, Sanft T, Moslehi JJ, Overholser L, Armenian S, Baker KS, et al. NCCN guidelines insights: survivorship, version 2.2020. J Natl Compr Canc Netw 2020;18(8):1016-23.
- 2. Rockson SG. Lymphedema. Am J Med 2001;110(4):288-95.
- 3. Oliver G, Kipnis J, Randolph GJ, Harvey NL. The lymphatic vasculature in the 21st century: novel functional roles in homeostasis and disease. Cell 2020;182(2):270-96.
- Rockson SG, Keeley V, Kilbreath S, Szuba A, Towers A. Cancer-associated secondary lymphoedema. Nat Rev Dis Primers 2019;5(1):22.
- 5. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 2013;14(6):500-15. Epub 2013 Mar 27.
- Hayes SC, Janda M, Ward LC, Reul-Hirche H, Steele ML, Carter J, et al. Lymphedema following gynecological cancer: results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. Gynecol Oncol 2017;146(3):623-9. Epub 2017 Jun 16.
- 7. Giorup CA, Groenvold M, Hendel HW, Dahlstroem K, Drzewiecki KT, Klausen TW, et al. Health-related quality of life in melanoma patients: impact of melanoma-related limb lymphoedema. Eur J Cancer 2017;85:122-32. Epub 2017 Sep 15.
- 8. Ridner SH, Dietrich MS, Niermann K, Cmelak A, Mannion K, Murphy B. A prospective study of the lymphedema and fibrosis continuum in patients with head and neck cancer. Lymphat Res Biol 2016;14(4):198-205. Epub 2016 Jun 15.
- Brown S, Campbell AC, Kuonqui K, Sarker A, Park HJ, Shin J, et al. The future of lymphedema: potential therapeutic targets for treatment. Curr Breast Cancer Rep 2023;1-9. Epub 2023 Jun 1.
- 10. Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer 2010;116(22):5138-49.

- 11. Anand A, Balasubramanian D, Subramanian N, Murthy S, Limbachiya S, Iyer S, et al. Secondary lymphedema after head and neck cancer therapy: a review. Lymphology 2018:51(3):109-18.
- 12. What is lymphedema? Toronto, ON: Canadian Lymphedema Framework; 2023. Available from: https://www.canadalymph.ca/what-is-it/. Accessed 2023 Aug 30.
- 13. Mehrara B. Clinical features and diagnosis of peripheral lymphedema. Waltham, MA: UpToDate; 2023. Available from: https://www.uptodate.com/contents/clinicalfeatures-and-diagnosis-of-peripheral-lymphedema?search=lymphedema&source= search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H33. Accessed 2023 Aug 30.
- 14. Chaput G, Ibrahim M, Towers A. Cancer-related lymphedema: clinical pearls for providers. Curr Oncol 2020;27(6):336-40. Epub 2020 Dec 1.
- 15. Attribution 2.0 Generic. Mountain View, CA: Creative Commons. Available from: https://creativecommons.org/licenses/by/2.0/. Accessed 2023 Sep 13.
- 16. Zuther JE, Norton S. Lymphedema management: the comprehensive guide for practitioners. 4th ed. New York, NY: Thieme Group; 2017.
- 17. Lymphoedema Framework. Best practice for the management of lymphoedema. International consensus. London, UK: Medical Education Partnership Ltd; 2006. Available from: https://www.lympho.org/uploads/files/files/Best_practice.pdf. Accessed 2023 Sep 13.
- 18. Stout Gergich NL, Pfalzer LA, McGarvey C, Springer B, Gerber LH, Soballe P. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer 2008;112(12):2809-19.
- 19. Armer JM, Radina ME, Porock D, Culbertson SD. Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res 2003;52(6):370-9
- 20. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology. Lymphology 2003;36(2):84-91.
- 21. DocHealer. Lymphedema staging for upper limbs. Own work, public domain. Wikimedia Commons: 2017, Available from: https://commons.wikimedia.org/wiki/ File:Upper_limb_lymphedema.jpg. Accessed 2023 Aug 30.
- 22. Attribution-ShareAlike 4.0 international. Mountain View, CA: Creative Commons. Available from: https://creativecommons.org/licenses/by-sa/4.0/deed.en. Accessed 2023 Sep 13.
- 23. DocHealer. Lymphedema staging for lower limbs. Own work, public domain. Wikimedia Commons; 2017. Available from: https://commons.wikimedia.org/wiki/ File:Lower_Limb_Lymphedema.png. Accessed 2023 Aug 30.
- 24. Kroenke K, Corrigan JD, Ralston RK, Zafonte R, Brunner RC, Giacino JT, et al. Effectiveness of care models for chronic disease management; a scoping review of systematic reviews. PM R 2023;10.1002/pmrj.13027. Epub 2023 Jun 17.
- 25. Armer JM, Ostby PL, Ginex PK, Beck M, Deng J, Fu MR, et al. ONS Guidelines™ for cancer treatment-related lymphedema. Oncol Nurs Forum 2020;47(5):518-38.
- 26. Cheville AL, McGarvey CL, Petrek JA, Russo SA, Taylor ME, Thiadens SRJ. Lymphedema management. Semin Radiat Oncol 2003;13(3):290-301.
- 27. Petrek JA, Pressman PI, Smith RA. Lymphedema: current issues in research and management. CA Cancer J Clin 2000;50(5):292-307.
- 28. Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin 2009;59(1):8-24.
- 29. Vignes S, Poizeau F, Dupuy A. Cellulitis risk factors for patients with primary or secondary lymphedema. J Vasc Surg Venous Lymphat Disord 2022;10(1):179-85.e1. Epub 2021 May 3
- 30. Grądalski T. Limb edema in patients with advanced disease-a pilot study of compression therapy combined with diuretics. Palliat Med Pract 2019;13(2):51-6.

This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to https://www.cfp.ca and click on the Mainpro+ link. Can Fam Physician 2023;69:691-5 (Eng), e206-10 (Fr). DOI: 10.46747/cfp.6910691

La traduction en français de cet article se trouve à https://www.cfp.ca dans la table des matières du numéro d'octobre 2023 à la page e206.